|
|
Blood, Vol. 110, Issue 2, 727-734, July 15, 2007
Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
Blood Pfeifer et al.
110: 727
Supplemental materials for: Pfeifer et al, Vol 110, Issue 2, 727-734
The following investigators contributed by enrolling and caring for patients in the randomized, multicenter trial that forms the basis for the analysis described in this manuscript:
Departments of Hematology and Oncology of the University Hospitals Münster (M. Stelljes)
Essen (U. Dührsen)
Tübingen (M. Schmalzing)
Berlin/Charité (P. leCoutre)
Mainz (J. Beck)
Ulm (M. Schmid)
Mannheim (M. Müller)
Freiburg (M. Lübbert)
Rostock (M. Freund)
Chemnitz (A. Thiel)
Berlin/Benjamin-Franklin (S. Schwartz)
Kiel (M. Kneba)
Marburg (A. Neubauer)
Heidelberg (J. Dengler)
Homburg/Saar (M. Pfreundschuh)
The St. Johannes Hospital, Duisburg (A.Giagounidis)
Klinikum Essen-Werden (M. Wattad)
Städtische Kliniken Krefeld (M.Planker)
St. Marien-Krankenhaus Siegen (W. Gassmann)
Klinikum Villingen-Schwenningen (W. Brugger)
Gütersloh (P. Düwel)
Klinikum Neukölln, Berlin (Grüneisen)
Traunstein (E. Hagenreiner)
Berlin (A. Matylis)
Oldenburg (C. Schimmelpfennig) (all in Germany).
|
|
